Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 117 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Flavivirus Infections Clear all

Conditions: Prevention of Zika Infection, Zika-Specific Immune Response
Interventions: VRC-ZKADNA090-00-VP; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dengue Fever, Dengue Hemorrhagic Fever, Dengue Virus
Interventions: Tetravalent CYD Dengue Vaccine , 5555 formulation, Tetravalent CYD Dengue Vaccine , 5553 formulation, Tetravalent CYD Dengue Vaccine, 4444 formulation; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: Hoover, Alabama • San Diego, California • Vallejo, California + 2 more

Conditions: Dengue Fever
Interventions: Tetravalent Dengue Vaccine (TDV); Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Anaheim, California • Hutchinson, Kansas

Conditions: Zika, Zika Virus Infection
Interventions: VLA1601, CpG 1018®, 3M-052-AF; Biological
Lead sponsor: Valneva Austria GmbH; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Chicago, Illinois • Sioux City, Iowa • Lincoln, Nebraska + 1 more

Conditions: Dengue
Interventions: TDENV-LAV, TDENV-PIV 4 µg + alum adjuvant; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 49 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Malaria Fever, Zika, Dengue Fever, Leptospirosis, Chikungunya Virus Infection
Interventions: Xpert Tropical Fever test; Diagnostic Test
Lead sponsor: Cepheid; Industry
Eligibility: 14 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Zika Virus, Zika Virus Infection, Virus Diseases, Flavivirus Infections, Flaviviral Diseases, Flaviviridae Infections, RNA Virus Infections
Interventions: VRC-ZKADNA090-00-VP, VRC-PBSPLA043-00-VP; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 15 Years to 35 Years
Enrollment: 2,428 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Miami, Florida • Edinburg, Texas • Houston, Texas

Conditions: Dengue
Interventions: Placebo (SC), Placebo (ID), Modified Live Tetravalent Chimeric Dengue Vaccine (SC), Modified Live Tetravalent Chimeric Dengue Vaccine (ID); Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Yellow Fever, Yellow Fever Immunisation
Interventions: ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Iowa City, Iowa • St Louis, Missouri

Conditions: Healthy, West Nile Fever, Healthy Volunteer, HV
Interventions: VRC-WNVDNA017-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dengue
Interventions: TDENV-PIV, TDENV-F17, Placebo; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 39 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Encephalitis, Japanese Encephalitis
Interventions: ChimeriVax-JE, Japanese Encephalitis vaccine, 0.9% Saline; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 2,004 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 16
States / cities: Burbank, California • Costa Mesa, California • Davis, California + 13 more

Conditions: Dengue
Interventions: TetraVax-DV Vaccine-Admixture 1, TetraVax-DV Vaccine-Admixture 2, TetraVax-DV Vaccine-Admixture 3, TetraVax-DV Vaccine-Admixture 4, Placebo, TetraVax-DV Vaccine-Admixture 5; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Burlington, Vermont

Conditions: Japanese Encephalitis
Interventions: ChimeriVax™-JE, JE-VAX®; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 820 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 5
States / cities: Chicago, Illinois • Shawnee Mission, Kansas • Missoula, Montana + 2 more

Conditions: Randomised Clinical Trial, Double Blind, Dengue, Challenge Test, Dose Escalation and Safety
Interventions: VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant, ALFQ adjuvant + Saline, rDEN3Delta30; Biological
Lead sponsor: VLP Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Yellow Fever
Interventions: Yellow Fever Vaccine, Leukapheresis, Fine-needle aspiration (FNA); Biological · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 239 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2024
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Dengue
Interventions: D1ME100 (dengue-1 premembrane/envelope DNA vaccine); Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 50 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Dengue
Interventions: YF-17D, TDV, Placebo; Biological · Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 11
States / cities: Mobile, Alabama • Pomona, California • Meridian, Idaho + 8 more

Conditions: Dengue Fever
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 6 Months to 11 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Tick-Borne Encephalitis, Encephalitis, Tick-Borne, Tick-Borne Disease, Glycoprotein E, Flavivirus, NSI Protein, Flavivirus
Interventions: FSME-IMMUN 0.5ml Baxter; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 2
States / cities: Bethesda, Maryland • Hamilton, Montana

Conditions: Zika Virus
Interventions: mRNA-1325, Placebo; Biological · Other
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: San Diego, California • Melbourne, Florida • Peoria, Illinois

Conditions: Dengue Shock Syndrome, Dengue Hemorrhagic Fever
Interventions: DEN4 Vaccine Candidate, DEN4 Vaccine Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Baltimore, Maryland • Burlington, Vermont

Conditions: Dengue
Interventions: rDEN1delta30, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Dengue
Interventions: TetraVax-DV-TV003, rDEN2∆30-7169, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Baltimore, Maryland • Burlington, Vermont

Search by objective public record fields.

VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults

Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults

Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

TDENV PIV and LAV Dengue Prime-boost Strategy

Xpert® Tropical Fever Test on GeneXpert® Edge X System

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents

Tetravalent Chimeric Dengue Vaccine Trial

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

Vaccine to Prevent West Nile Virus Disease

TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant

Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.

Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX

Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults

Human Immune Responses to Yellow Fever Vaccination

Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

Diagnosis and Characterization of Dengue Fever in Children

Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)

Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects

Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus

Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine

Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults